| Vaccines |
1 |
1 |
| Child |
0 |
0.83 |
| COVID-19 |
0 |
0.75 |
| Tdap Vaccine |
0 |
0.6 |
| Acute Respiratory Distress Syndrome |
0 |
0.5 |
| Id Reaction |
0 |
0.49 |
| Patient Safety |
0 |
0.46 |
| Pain Management |
0 |
0.45 |
| Severe Acute Respiratory Syndrome (SARS) |
0 |
0.65 |
| Delayed Hypersensitivity Reaction |
0 |
0.38 |
| Dermatitis |
0 |
0.3 |
| Immunization |
0 |
0.5 |
| Anaphylaxis |
0 |
0.21 |
| Kansas |
0 |
0.15 |
| Arthralgia |
0 |
0.12 |
| Pain |
0 |
0.11 |
| Myalgia |
0 |
0.1 |
| Diphtheria |
0 |
0.07 |
| Femoral |
0 |
0.07 |
| Fever |
0 |
0.07 |
| Tetanus |
0 |
0.07 |
| Adolescent Medicine |
0 |
0.04 |
| Adverse Effects |
0 |
0.04 |
| Allergy |
0 |
0.04 |
| Biopsy |
0 |
0.04 |
| Brachial |
0 |
0.04 |
| Eosinophils |
0 |
0.04 |
| Fatigue |
0 |
0.04 |
| Pathogenesis |
0 |
0.04 |
| Pruritus |
0 |
0.04 |
| Referral |
0 |
0.04 |
| Headache |
0 |
0.02 |